Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D C Stump

Showing results (41-50 of 58) with videos related to

Pageof 6
Sort By:
Thrombosis and Haemostasis|December 29, 1989
Indirect activation of blood coagulation in colon cancerM Z Wojtukiewicz, L R Zacharski, V A Memoli, et al.
Anticancer Research|May 1, 1990
Fibrinogen-fibrin transformation in situ in renal cell carcinomaM Z Wojtukiewicz, L R Zacharski, V A Memoli, et al.
Thrombosis Research|July 15, 1989
Absence of components of coagulation and fibrinolysis pathways in situ in mesotheliomaM Z Wojtukiewicz, L R Zacharski, V A Memoli, et al.
Blood|April 11, 1992
Anticoagulant and fibrinolytic activities are promoted, not retarded, in vivo after thrombin generation in the presence of a monoclonal antibody that inhibits activation of protein CF B Taylor, H Hoogendoorn, A C Chang, et al.
Cancer|September 1, 1991
Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissuesD L Ornstein, L R Zacharski, V A Memoli, et al.
Cancer|March 1, 1991
Fibrin formation on vessel walls in hyperplastic and malignant prostate tissueM Z Wojtukiewicz, L R Zacharski, V A Memoli, et al.
Journal of the American College of Cardiology|March 1, 1993
Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy. The TAMI Study GroupT C Wall, R M Califf, S G Ellis, et al.
The American Journal of Cardiology|April 1, 1988
Comparison of two dose regimens of intravenous tissue plasminogen activator for acute myocardial infarctionE J Topol, B S George, D J Kereiakes, et al.
American Heart Journal|January 3, 2001
Determination of a weight-adjusted dose of TNK-tissue plasminogen activatorF Wang-Clow, N L Fox, C P Cannon, et al.
Annals of Internal Medicine|August 15, 1991
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II TrialE G Bovill, M L Terrin, D C Stump, et al.
Pageof 6

Showing results (41-50 of 58) with videos related to

Sort By:
Pageof 6
Thrombosis and Haemostasis|December 29, 1989
Indirect activation of blood coagulation in colon cancerM Z Wojtukiewicz, L R Zacharski, V A Memoli, et al.
Anticancer Research|May 1, 1990
Fibrinogen-fibrin transformation in situ in renal cell carcinomaM Z Wojtukiewicz, L R Zacharski, V A Memoli, et al.
Thrombosis Research|July 15, 1989
Absence of components of coagulation and fibrinolysis pathways in situ in mesotheliomaM Z Wojtukiewicz, L R Zacharski, V A Memoli, et al.
Blood|April 11, 1992
Anticoagulant and fibrinolytic activities are promoted, not retarded, in vivo after thrombin generation in the presence of a monoclonal antibody that inhibits activation of protein CF B Taylor, H Hoogendoorn, A C Chang, et al.
Cancer|September 1, 1991
Coexisting macrophage-associated fibrin formation and tumor cell urokinase in squamous cell and adenocarcinoma of the lung tissuesD L Ornstein, L R Zacharski, V A Memoli, et al.
Cancer|March 1, 1991
Fibrin formation on vessel walls in hyperplastic and malignant prostate tissueM Z Wojtukiewicz, L R Zacharski, V A Memoli, et al.
Journal of the American College of Cardiology|March 1, 1993
Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy. The TAMI Study GroupT C Wall, R M Califf, S G Ellis, et al.
The American Journal of Cardiology|April 1, 1988
Comparison of two dose regimens of intravenous tissue plasminogen activator for acute myocardial infarctionE J Topol, B S George, D J Kereiakes, et al.
American Heart Journal|January 3, 2001
Determination of a weight-adjusted dose of TNK-tissue plasminogen activatorF Wang-Clow, N L Fox, C P Cannon, et al.
Annals of Internal Medicine|August 15, 1991
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II TrialE G Bovill, M L Terrin, D C Stump, et al.
Pageof 6